Inhibikase Therapeutics
Logotype for Inhibikase Therapeutics Inc

Inhibikase Therapeutics (IKT) investor relations material

Inhibikase Therapeutics Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Inhibikase Therapeutics Inc
Jefferies Global Healthcare Conference summary16 Nov, 2026

Phase III program and milestones

  • Phase III launched; 28 countries approved and 79 sites active within the prior 4–6 months, with execution meeting internal expectations.

  • H1 2027 safety update expected after 50 patients have 12 weeks of data; planned disclosure is limited to DSMB review and confirmation the trial can continue, tied to a $55M financing tranche.

  • Mid-2028 Part A: 140 patients, powered for primary PVR endpoint; six-minute walk and other secondary data also expected.

  • Mid-2029 pivotal Part B data expected; target enrollment is 340 patients, with Part A and B using the same sites and providing independent data sets for a potential filing package.

Efficacy and product profile

  • IKT-001 is a prodrug designed to remain intact in the GI tract before converting to imatinib in plasma; expected to retain imatinib-like efficacy.

  • Management views a 20% PVR reduction and 20-meter six-minute-walk improvement as clinically meaningful; hopes and expectations are closer to IMPRES results of ~30% reductions and ~30-meter improvement.

  • Part A six-minute-walk results are expected to show trends, but the 140-patient segment is not powered for statistical significance on that measure.

Safety and dosing approach

  • Preclinical work suggests lower GI effects than imatinib; clinical studies will test this. Systemic imatinib-associated effects, including edema, are still expected.

  • Planned titration to higher dose takes eight weeks; 300, 400 and 500 mg doses are available, with investigator and patient discretion to step down if needed to support trial retention.

  • Protocol training distinguishes edema from clinical worsening; multiple criteria define worsening events, addressing a concern raised in IMPRES.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Inhibikase Therapeutics earnings date

Logotype for Inhibikase Therapeutics Inc
Q4 202625 Mar, 2027
Inhibikase Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Inhibikase Therapeutics earnings date

Logotype for Inhibikase Therapeutics Inc
Q4 202625 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Inhibikase Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases and cancers. The company’s research primarily targets diseases related to protein misfolding, such as Parkinson's disease, by aiming to inhibit the malfunction of key cellular processes. Inhibikase Therapeutics develops therapeutics that aim to modify the progression of these diseases and improve patient outcomes. Its approach includes addressing both neurological and oncological conditions through small-molecule therapeutics. The company is headquartered in Atlanta, Georgia, and its shares are listed on the NASDAQ.